GLPwatch

Activation of the renal GLP-1R leads to expression of <i>Ren1</i> in the renal vascular tree.

Endocrinol Diabetes Metab · 2021

Last updated 2026-05-28

A study in mice found that a single or repeated dose of the GLP-1 drugs liraglutide or semaglutide increased the expression of a gene called *Ren1* in the muscle cells of kidney blood vessels compared to a control group, with statistical significance (p < .0001). This suggests that GLP-1 drugs may affect kidney function by influencing this gene.

AI summary of the abstract below.

JournalEndocrinol Diabetes Metab, 2021
Citations5
Relative citation ratio0.33
NIH percentile20
Molecules
Conditions studied Chronic Kidney Disease

Abstract

The GLP-1 receptor (GLP-1R) in the kidney is expressed exclusively in vascular smooth muscle cells in arteries and arterioles. Downstream effects of the activation of the renal vascular GLP-1R are elusive but may involve regulation of the renin-angiotensin-aldosterone system (RAAS). The expression of in the mouse renal vasculature was investigated by in situ hybridization after a single subcutaneous dose of liraglutide, semaglutide and after repeated injections of liraglutide. Single and repeated exposure to GLP-1R agonists induced expression of in the renal vascular smooth muscle cell compartment compared with vehicle injected controls ( < .0001) for both semaglutide and liraglutide. The present data show a robust induction of expression in the vascular smooth muscle cells of the kidney after single and repeated GLP-1R activation and this renin recruitment may be involved in the effects of GLP-1R agonist treatment on kidney disease.

Verbatim abstract via PubMed 34277961 ↗